• Explore /
  • Poster
  • / MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

Abstract Poster

Authors

Shilpa Gupta

Shilpa Gupta

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Shilpa Gupta , Karla V. Ballman , Andrea B. Apolo , Srikala S. Sridhar , Ronald C. Chen , Yujia Wen , Aihua Edward Yen , Petros Grivas , Alan Tan , Shiva Baghaie , Matt D. Galsky , Michael J. Morris , Jonathan E. Rosenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05092958

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS714)

DOI

10.1200/JCO.2024.42.4_suppl.TPS714

Abstract #

TPS714

Poster Bd #

M14

Abstract Disclosures

Similar Posters

First Author: Shilpa Gupta

First Author: Shilpa Gupta

First Author: Inkeun Park

First Author: Haojie Li